Berkeley Lights BLI
Berkeley Lights' $2M Beacon is a flow-cytometer knockoff customers call a clunker; with flat sales, fleeing insiders, and 50x-cheaper rivals, Scorpion pegs BLI at $0.
Thesis
Scorpion Capital argues Berkeley Lights is a one-product company whose $2 million Beacon — marketed as 'Digital Cell Biology' — is a glorified flow cytometer and microfluidics chip, functionally duplicated by Sony, Thermo Fisher, 10X Genomics, Abcellera and Isoplexis at 3-5% of the price. Across 24 interviews with 7 ex-BLI employees and scientists at 14 of its largest customers (Amgen, Bristol Myers Squibb, Pfizer, Novartis, AbbVie, Gilead, Takeda, Lonza, Samsung Biologics, IQVIA), Scorpion documents 50-100% error rates, 80-90% failure on complex antibodies, a saturated TAM of only ~300 machines worldwide, and press releases that misrepresent customer relationships with UPenn and Bayer. Meanwhile product revenue is flat for two years, consumables usage is collapsing to 2-3 runs per machine per quarter, the CFO and Chief Accounting Officer just resigned, VCs (Sequoia, Walden, Celesta) and Nikon dumped their entire stakes post-IPO, and A/R has spiked 50% while sales fell 11%. Target price: $0.
SCQA
Berkeley Lights is a single-product Nasdaq company selling the $2 million Beacon optofluidic instrument to pharma and biotech for antibody discovery and cell-line development, trading at a $2.3B market cap and 27x sales.
Across 24 interviews, 14 of BLI's largest customers describe a $2M clunker with 50-100% error rates, negligible TAM, saturated sales, and competitors like Abcellera and 10X Genomics delivering the same workflows at 3-5% of the price.
Short the stock: Scorpion Capital is publicly short BLI and expects the company to slash or miss 2021 guidance in Q3/Q4 as installed-base utilization, consumables revenue, and channel quality continue to deteriorate.
Target price $0 — BLI has no earnings or cash-flow value, no growth left given flat sales, and no asset value as customers publicly trash the product; downside tracks FLDM's ~4x sales collapse.
The three reasons
- 1
14 of BLI's largest customers call the $2M Beacon a clunker with 50% error rates
- 2
Priced 20x peers; Abcellera and 10X Genomics deliver same workflow at 3-5% of cost
- 3
VCs and Nikon dumped stakes post-IPO; CFO fled; sales flat 2 years, A/R up 50%
Primary demands
- Short BLI; target price $0
- Stop relying on misleading press releases and customer testimonials
- Expect guidance cut or miss in Q3/Q4 2021
KPIs cited
Pattern membership
Precedents cited
- Affymetrix (AFFX) post-IPO crash, acquired at 3.5x sales
- Fluidigm (FLDM) hype-and-crash to ~$500MM market cap
- Zymergen (ZY) 72% single-day drop, Aug 2021
- Intrexon synthetic-biology short
Composition what's on the 158 slides
Slide gallery ·
Notes
Classic Scorpion Capital forensic short — 158 pages built on 24 interviews (7 ex-BLI employees, 17 scientists at 14 customers). Structure: Part 1 (pp 8-134) = red flags + customer interviews organized by pharma (Amgen, BMS, Pfizer, Novartis, AbbVie, IQVIA, Gilead, Takeda, Harbour, Lonza, Samsung, CZ Biohub, UCSF/NIH, Gingko); Part 2 (pp 135-158) = 7 ex-employee interviews on product-market fit, pricing, competition. Rhetoric relies heavily on underlined/bolded damning phrases, yellow-highlighted expert quotes, and side-by-side hype-vs-reality screenshots. No named human author — signed only as 'Scorpion Capital'. Cover explicitly discloses short position. Target price $0.